| Literature DB >> 26401136 |
Christopher Amaloo1, Daryl P Nazareth2, Lalith K Kumaraswamy3.
Abstract
BACKGROUND: Volumetric modulated arc therapy (VMAT) has quickly become accepted as standard of care for the treatment of prostate cancer based on studies showing it is able to provide faster delivery with adequate target coverage and reduced monitor units while maintaining organ at risk (OAR) sparing. This study aims to demonstrate the potential to increase dose conformality with increased planner control and OAR sparing using a hybrid treatment technique compared to VMAT.Entities:
Keywords: VMAT; hybrid; planning; prostate
Year: 2015 PMID: 26401136 PMCID: PMC4577227 DOI: 10.1515/raon-2015-0018
Source DB: PubMed Journal: Radiol Oncol ISSN: 1318-2099 Impact factor: 2.991
Patient characteristics
| 1 | T1c | 4+3=7/10 | 6.0 | 70 |
| 2 | T1c | 3+3=6/10 | 4.4 | 67 |
| 3 | T1c | 3+4=7/10 | 9.9 | 61 |
| 4 | T2a | 4+5=9/10 | 24.4 | 81 |
| 5 | T2c | 3+3=6/10 | 10.8 | 67 |
| 6 | T2a | 5+4=9/10 | 9.5 | 74 |
| 7 | T1c | 3+4=7/10 | 6.1 | 70 |
| 8 | T1c | 4+3=7/10 | 8.8 | 60 |
| 9 | T1c/T2a | 4+3=7/10 | 4.8 | 69 |
| 10 | T1c | 4+3=7/10 | 6.8 | 63 |
| 11 | T2b/T3a | 4+5=9/10 | 14.2 | 63 |
PSA = prostate-specific antigen; Pt = patient
FIGURE 1.Diagram showing additional structures to control rectal dose.
FIGURE 2.Dose distribution for typical hybrid (A) and 2 arc volumetric modulated arc therapy (VMAT) (B). plans with color wash of 95% of the prescription dose.
Planning treatment volume (PTV) coverage, monitor units, and integral dose for delivery of plans
| 1 | Hybrid | 0.98 | 92.8% | 108.5% | 103.0% | 686 | 308.1 |
| VMAT | 1.08 | 95.5% | 108.1% | 101.4% | 867 | 303.7 | |
| 2 | Hybrid | 0.99 | 91.3% | 107.1% | 102.3% | 817 | 186.5 |
| VMAT | 1.15 | 97.5% | 107.6% | 102.0% | 697 | 198.8 | |
| 3 | Hybrid | 1.00 | 94.4% | 107.6% | 102.3% | 616 | 255.8 |
| VMAT | 1.05 | 96.2% | 106.2% | 101.3% | 592 | 255.3 | |
| 4 | Hybrid | 1.05 | 95.0% | 107.7% | 102.5% | 743 | 200.3 |
| VMAT | 1.08 | 97.5% | 109.4% | 101.5% | 574 | 196.3 | |
| 5 | Hybrid | 1.07 | 94.9% | 106.6% | 102.4% | 521 | 232.0 |
| VMAT | 1.12 | 96.9% | 106.9% | 101.3% | 796 | 233.1 | |
| 6 | Hybrid | 1.15 | 96.8% | 111.0% | 101.6% | 600 | 216.3 |
| VMAT | 1.32 | 91.6% | 109.8% | 102.0% | 602 | 208.6 | |
| 7 | Hybrid | 0.97 | 94.2% | 107.1% | 102.8% | 542 | 201.3 |
| VMAT | 0.97 | 94.7% | 106.1% | 102.3% | 487 | 201.8 | |
| 8 | Hybrid | 1.03 | 95.2% | 110.0% | 102.6% | 729 | 133.5 |
| VMAT | 1.03 | 94.8% | 107.4% | 101.7% | 598 | 132.2 | |
| 9 | Hybrid | 1.09 | 95.3% | 109.7% | 102.3% | 786 | 254.7 |
| VMAT | 1.17 | 97.4% | 106.2% | 101.6% | 622 | 263.5 | |
| 10 | Hybrid | 1.13 | 96.2% | 109.3% | 101.8% | 603 | 178.5 |
| VMAT | 1.03 | 92.6% | 107.3% | 102.2% | 610 | 175.6 | |
| 11 | Hybrid | 1.00 | 96.0% | 106.6% | 102.1% | 521 | 165.6 |
| VMAT | 1.14 | 98.1% | 106.0% | 101.7% | 587 | 175.5 | |
| AVE | Hybrid | 1.04 | 94.74% | 108.29% | 102.34% | 651.27 | 212.05 |
| VMAT | 1.10 | 95.71% | 107.36% | 101.73% | 639.27 | 213.13 |
AVE = average; CI = confidence interval; MU = monitor units; Pt = patient; VMAT = volumetric modulated arc therapy
Organ-at-Risk constraints for bladder, rectum, femora and body
|
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30.66 | 42.35 | 52.12 | 69.11 | 30.75 | 42.98 | 54.31 | 69.50 | 38.49 | 17.31 | 37.13 | 17.18 | |
| 29.10 | 40.56 | 50.62 | 66.72 | 30.66 | 41.69 | 52.83 | 67.34 | 44.86 | 15.41 | 46.02 | 18.25 | |
| 1.56 | 1.79 | 1.50 | 2.40 | 0.09 | 1.28 | 1.48 | 2.16 | −6.37 | 1.90 | −8.89 | −1.07 | |
DIFF = difference; f. = femur; VMAT = volumetric modulated arc therapy
FIGURE 3.Dose volume histogram (DVH) comparison of some planning treatment volume (PTV), rectum, and bladder between the hybrid technique and the two field volumetric modulated arc therapy (VMAT) technique.